Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

  • Technology appraisal guidance
  • TA269
  • Published: 
  • Last updated: 
Download guidance (PDF)

1 Recommendations

1.1

Vemurafenib is recommended as an option for treating BRAF V600 mutation-positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.